In the first 3 weeks after disease onset, the S-, RBD-, and N-specific IgM/IgG levels were higher in patients with mild/moderate COVID-19 than in those with severe/critical disease, implying the weak antibody response in the early stage of infection may be associated with the disease progression. This evidence concerns the gene CD40LG and COVID-19.